Clinic
Crouse Health Hospital, INC.
Crouse Health Hospital, INC. was paid $78.65M by Medicaid between Jan 2018 and Dec 2024, across 277 billing codes. Its largest line is H0020, Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) — 22% of everything it billed.
33Billing provider infoCROUSE HEALTH HOSPITAL, INC.
SYRACUSE, NY 13210
SYRACUSE, NY 13210
33aNPI1033107743assigned 10/07/2005
33bProvider typeMethadone Clinic
28Total paid$78.65M
24GClaims1,546,511
24DCodes billed277
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Methadone Clinic providers in New York
Rank by total paid#2 of 21
Median peer was paid$4.89M
This provider vs. median16×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 11,093 | $932K | |
| 2019 | 100,176 | $3.79M | |
| 2020 | 240,028 | $11.26M | |
| 2021 | 282,114 | $13.06M | |
| 2022 | 328,955 | $19.97M | |
| 2023 | 362,952 | $19.57M | |
| 2024incomplete | 221,193 | $10.06M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| H0020 | Alcohol and/or drug services; methadone administration and/or service (provision of the drug by a licensed program) | 22% | 660,632 | 37,548 | $17.66M |
| G2067 | Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) | 8.7% | 41,191 | 13,337 | $6.88M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.3% | 37,448 | 34,619 | $4.94M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 5.8% | 23,781 | 22,660 | $4.53M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 4.8% | 17,297 | 15,759 | $3.74M |
| 36415 | Collection of venous blood by venipuncture | 4.6% | 48,766 | 44,086 | $3.58M |
| 96361 | Intravenous infusion, hydration; each additional hour | 3.6% | 12,113 | 10,982 | $2.79M |
| 90832 | Psychotherapy session, about 30 minutesPsychotherapy, 30 minutes with patient | 2.6% | 21,448 | 13,769 | $2.07M |
| H0005 | Alcohol and/or drug services; group counseling by a clinician | 2.6% | 35,602 | 7,014 | $2.02M |
| 70450 | Computed tomography, head or brain; without contrast material | 2.3% | 6,186 | 6,020 | $1.81M |
| H2036 | Alcohol and/or other drug treatment program, per diem | 1.8% | 13,581 | 1,666 | $1.44M |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 1.8% | 2,635 | 2,594 | $1.41M |
265 more codes
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.8% | 4,884 | $1.41M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.5% | 11,514 | $1.15M |
| 99214 | Doctor's office visit, returning patient (more involved) | 1.4% | 8,823 | $1.14M |
| 59025 | Fetal non-stress test | 1.4% | 6,286 | $1.10M |
| G0397 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and intervention, greater than 30 minutes | 1.4% | 7,934 | $1.08M |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.4% | 46,050 | $1.07M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 1.1% | 530 | $880K |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 6,107 | $765K |
| G0396 | Alcohol and/or substance (other than tobacco) misuse structured assessment (e.g., audit, dast), and brief intervention 15 to 30 minutes | <1% | 7,285 | $761K |
| 86900 | <1% | 6,431 | $751K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 2,278 | $682K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 3,312 | $680K |
| 99285 | Emergency room visit (most serious) | <1% | 5,392 | $646K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,992 | $609K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 5,607 | $554K |
| 80076 | <1% | 22,256 | $549K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 2,853 | $513K |
| 87631 | <1% | 2,786 | $488K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 1,957 | $488K |
| H0004 | Behavioral health counseling and therapy, per 15 minutes | <1% | 10,145 | $476K |
| 76770 | <1% | 906 | $464K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 1,332 | $426K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 348 | $396K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 1,316 | $391K |
| 83880 | <1% | 3,261 | $384K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 2,734 | $382K |
| 58661 | <1% | 153 | $342K | |
| A0225 | Ambulance service, neonatal transport, base rate, emergency transport, one way | <1% | 558 | $336K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 5,285 | $322K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 3,738 | $308K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 945 | $253K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 5,719 | $253K |
| H0001 | Alcohol and/or drug assessment | <1% | 1,656 | $241K |
| 88307 | <1% | 726 | $235K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,034 | $232K |
| 97161 | <1% | 2,031 | $219K | |
| 76801 | <1% | 2,390 | $216K | |
| H2001 | Rehabilitation program, per 1/2 day | <1% | 2,706 | $215K |
| 90834 | Psychotherapy session, about 45 minutes | <1% | 1,349 | $175K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 1,123 | $173K |
| 88342 | <1% | 585 | $168K | |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 1,535 | $165K |
| 80053 | Comprehensive metabolic panel | <1% | 6,555 | $147K |
| G0378 | Hospital observation service, per hour | <1% | 2,614 | $146K |
| 86901 | <1% | 6,422 | $129K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,049 | $129K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 2,880 | $128K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 1,201 | $127K |
| 93970 | <1% | 257 | $124K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 2,459 | $114K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,045 | $111K |
| H0002 | Behavioral health screening to determine eligibility for admission to treatment program | <1% | 632 | $104K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 1,487 | $103K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 5,225 | $103K |
| 86850 | <1% | 6,330 | $99K | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 55 | $96K |
| H0038 | Self-help/peer services, per 15 minutes | <1% | 1,466 | $94K |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 814 | $90K |
| 58558 | <1% | 63 | $87K | |
| 70486 | <1% | 699 | $75K | |
| 97162 | <1% | 512 | $70K | |
| 47562 | <1% | 25 | $69K | |
| 93971 | <1% | 1,153 | $68K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,483 | $66K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 112 | $61K |
| 93017 | <1% | 409 | $60K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 970 | $54K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 403 | $54K |
| 97803 | <1% | 536 | $49K | |
| 99291 | Critical care, evaluation and management of the critically ill patient, first 30-74 minutes | <1% | 401 | $47K |
| 72131 | <1% | 267 | $47K | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 144 | $44K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 1,026 | $39K |
| 82803 | <1% | 552 | $38K | |
| 10060 | <1% | 118 | $36K | |
| 87641 | <1% | 482 | $36K | |
| 12001 | <1% | 88 | $34K | |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 426 | $32K |
| 70498 | <1% | 157 | $31K | |
| 87522 | Neg quan hep c or qual rna | <1% | 874 | $31K |
| 97802 | <1% | 316 | $30K | |
| 29125 | <1% | 150 | $30K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 7,017 | $28K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 62 | $27K |
| 82962 | <1% | 8,250 | $27K | |
| 86703 | <1% | 1,102 | $25K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 349 | $25K |
| 85027 | <1% | 7,076 | $23K | |
| 83690 | <1% | 12,480 | $23K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 20,551 | $22K |
| 76641 | <1% | 972 | $21K | |
| 97165 | <1% | 231 | $20K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 3,545 | $20K |
| 90715 | <1% | 607 | $18K | |
| 76830 | Ultrasound, transvaginal | <1% | 659 | $16K |
| 93351 | <1% | 50 | $15K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 185 | $15K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,869 | $14K |
| 70491 | <1% | 45 | $14K | |
| 85055 | <1% | 309 | $13K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 372 | $13K |
| 80061 | Lipid panel | <1% | 443 | $12K |
| 74018 | <1% | 1,958 | $12K | |
| 84702 | <1% | 8,894 | $11K | |
| 95816 | <1% | 66 | $11K | |
| 88304 | <1% | 372 | $11K | |
| J7297 | Levonorgestrel-releasing intrauterine contraceptive system (liletta), 52 mg | <1% | 14 | $10K |
| 12002 | <1% | 26 | $10K | |
| 12011 | <1% | 27 | $10K | |
| 71045 | Radiologic examination, chest; single view | <1% | 7,601 | $9K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 13,897 | $9K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 41 | $7K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 40,148 | $7K |
| 70496 | <1% | 129 | $7K | |
| 86920 | <1% | 38 | $6K | |
| 83735 | <1% | 7,408 | $6K | |
| 36430 | <1% | 15 | $6K | |
| G2078 | Take-home supply of methadone; up to 7 additional day supply (provision of the services by a medicare-enrolled opioid treatment program); list separately in addition to code for primary procedure | <1% | 324 | $6K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 974 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 3,235 | $6K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 59 | $5K |
| P9016 | Red blood cells, leukocytes reduced, each unit | <1% | 14 | $5K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 9,801 | $5K |
| 81003 | <1% | 23,382 | $4K | |
| 93325 | <1% | 53 | $4K | |
| 88341 | <1% | 58 | $4K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 13 | $4K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,390 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 132 | $4K |
| 87340 | <1% | 1,226 | $3K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 27 | $3K |
| 72110 | <1% | 203 | $3K | |
| 87640 | <1% | 290 | $3K | |
| 36569 | <1% | 12 | $2K | |
| 88112 | <1% | 12 | $2K | |
| 73564 | <1% | 1,170 | $2K | |
| 77065 | Tomosynthesis, mammo | <1% | 28 | $2K |
| 88302 | <1% | 71 | $2K | |
| M0222 | Intravenous injection, bebtelovimab, includes injection and post administration monitoring | <1% | 20 | $2K |
| 87040 | <1% | 1,077 | $2K | |
| 82570 | <1% | 1,074 | $2K | |
| 86803 | <1% | 881 | $2K | |
| 87070 | <1% | 1,117 | $2K | |
| 87075 | <1% | 249 | $2K | |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | <1% | 2,547 | $2K |
| 72100 | <1% | 293 | $1K | |
| 73030 | <1% | 745 | $1K | |
| 86780 | <1% | 699 | $1K | |
| 85730 | <1% | 2,467 | $1K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 83 | $1K |
| 84484 | <1% | 13,942 | $1K | |
| 99223 | Prolong inpt eval add15 m | <1% | 15 | $1K |
| 73630 | <1% | 1,053 | $1K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 892 | $1K |
| 87077 | <1% | 3,516 | $986.35 | |
| 73610 | <1% | 941 | $864.51 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 5,093 | $802.74 |
| 0031A | <1% | 20 | $800.00 | |
| 87480 | <1% | 4,483 | $771.17 | |
| 76819 | Fetal biophysical profile; without non-stress testing | <1% | 16 | $703.65 |
| 85610 | <1% | 4,034 | $621.50 | |
| 84703 | <1% | 5,969 | $469.28 | |
| 84100 | <1% | 1,571 | $467.07 | |
| 72050 | <1% | 43 | $438.61 | |
| 80358 | <1% | 207 | $410.76 | |
| 87186 | <1% | 2,711 | $403.56 | |
| 85379 | <1% | 1,795 | $317.80 | |
| 81002 | <1% | 453 | $314.36 | |
| 87660 | <1% | 4,483 | $306.76 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 219 | $260.00 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 256 | $243.38 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 36 | $240.00 |
| 76536 | <1% | 15 | $234.08 | |
| 87510 | <1% | 4,483 | $224.28 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 540 | $203.73 |
| 83605 | <1% | 1,091 | $202.55 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,108 | $197.39 |
| 73130 | <1% | 475 | $180.74 | |
| 72170 | <1% | 39 | $179.08 | |
| 80321 | <1% | 208 | $171.61 | |
| 86140 | <1% | 1,115 | $124.15 | |
| 84439 | <1% | 170 | $108.00 | |
| 73110 | <1% | 306 | $100.25 | |
| 87205 | <1% | 1,113 | $97.71 | |
| J2704 | Injection, propofol, 10 mg | <1% | 5,406 | $97.22 |
| A9573 | Injection, gadopiclenol, 1 ml | <1% | 15 | $82.62 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 7,794 | $74.34 |
| 73502 | <1% | 65 | $74.29 | |
| 73590 | <1% | 134 | $71.19 | |
| 80354 | <1% | 143 | $70.91 | |
| 96376 | <1% | 343 | $62.00 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 9,279 | $61.68 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 442 | $51.46 |
| 83615 | <1% | 1,343 | $45.91 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 882 | $41.12 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 11,850 | $39.59 |
| 86308 | <1% | 1,011 | $35.48 | |
| 85651 | <1% | 456 | $33.80 | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,861 | $30.72 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 2,132 | $30.43 |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 274 | $30.06 |
| 84550 | <1% | 1,382 | $29.54 | |
| 74019 | <1% | 103 | $27.00 | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 3,241 | $26.69 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,401 | $25.88 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,504 | $24.20 |
| 71101 | <1% | 75 | $21.80 | |
| 84156 | <1% | 1,030 | $21.51 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 4,102 | $20.95 |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 482 | $16.10 |
| 80349 | <1% | 80 | $15.15 | |
| 80361 | <1% | 110 | $15.15 | |
| 82550 | <1% | 212 | $15.14 | |
| 82010 | <1% | 100 | $12.94 | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 1,645 | $11.42 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,929 | $11.13 |
| 80324 | <1% | 32 | $10.10 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,569 | $8.61 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 2,697 | $8.52 |
| 73140 | <1% | 71 | $5.92 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,082 | $5.24 |
| 80353 | <1% | 52 | $5.05 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 472 | $4.80 |
| 73090 | <1% | 64 | $4.12 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 2,084 | $3.58 |
| J7614 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 0.5 mg | <1% | 244 | $2.58 |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 130 | $1.77 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 34 | $1.35 |
| J1815 | Injection, insulin, per 5 units | <1% | 383 | $0.51 |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 1,264 | $0.05 |
| C1769 | Guide wire | 0% | 290 | $0.00 |
| 99153 | Mod sedat endo service >5yrs | 0% | 13 | $0.00 |
| 88300 | 0% | 122 | $0.00 | |
| J2470 | Injection, pantoprazole sodium, 40 mg | 0% | 231 | $0.00 |
| J8540 | Dexamethasone, oral, 0.25 mg | 0% | 80 | $0.00 |
| J7612 | Levalbuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 0.5 mg | 0% | 114 | $0.00 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | 0% | 148 | $0.00 |
| J2371 | Injection, phenylephrine hydrochloride, 20 micrograms | 0% | 12 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 16 | $0.00 |
| 93320 | 0% | 24 | $0.00 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 14 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 15 | $0.00 |
| J3411 | Injection, thiamine hcl, 100 mg | 0% | 12 | $0.00 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 442 | $0.00 |
| 94664 | 0% | 41 | $0.00 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 304 | $0.00 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | 0% | 187 | $0.00 |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 410 | $0.00 |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 106 | $0.00 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | 0% | 91 | $0.00 |
| 99152 | 0% | 129 | $0.00 | |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 38 | $0.00 |
| 80179 | 0% | 12 | $0.00 | |
| 84481 | 0% | 13 | $0.00 | |
| 73080 | 0% | 24 | $0.00 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 16 | $0.00 |
| J2550 | Injection, promethazine hcl, up to 50 mg | 0% | 29 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 18 | $0.00 |
| 80299 | 0% | 43 | $0.00 | |
| J1953 | Injection, levetiracetam, 10 mg | 0% | 59 | $0.00 |
| S5551 | Insulin, most rapid onset (lispro or aspart); 5 units | 0% | 18 | $0.00 |
| S0077 | Injection, clindamycin phosphate, 300 mg | 0% | 13 | $0.00 |
| 80346 | 0% | 18 | $0.00 | |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 59 | $0.00 |
| 80143 | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGALVIN, MOLLY (DIRECTOR OF REIMBURSEMENT & PATIENT)